Dissecting the cellular architecture of breast cancer brain metastases reveals prognostically distinct immune landscapes

Breast cancer brain metastases (BCBM) are a severe condition with high demand for improved personalized treatment, but a comprehensive understanding of BCBM immune-microenvironment heterogeneity and susceptibility to immunotherapy is lacking. Here, we multimodally profile the immune niche in a vast, clinically annotated cohort of BCBM applying tissue cytometry, bulk and single nuclei RNA-sequencing, and spatial transcriptomics, complemented by flow cytometric and functional studies in patient-derived organoids. Here the spatial and snRNAseq data is deposited.